KYAN Technologies Pte. Ltd. (“KYAN”) announces the publication of study results in Experimental Hematology & Oncology, with the publication title: “Combinatorial functionomics identifies HDAC6-dependent molecular vulnerability of radio-resistant head and neck cancer.”
In this study, KYAN’s Optim.AI™ platform (also known as “QPOP”), was applied to identify an epigenetic based therapeutic strategy in radioresistant head and neck cancer (RR-HNC). The study identified a critical role of HDAC6 in RR-HNC. Furthermore, a four‑gene biomarker signature that may predict HDAC6-related radio-resistance was identified from two independent patient cohorts through multi-omic analysis that pairs functionomics with transcriptomics.
“We are extremely excited by the results of this study as it exhibits the value that we can add to drug development with combinatorial biomarker discovery,” said Hugo Saavedra, Chief Executive Officer of KYAN.
KYAN’s Chief Scientific Officer, Dr. Edward Chow, added, “We are very proud of the work done by our collaborators at National University of Singapore and National Cancer Centre Singapore to demonstrate the use of Optim.AI™ towards novel target identification in a difficult to treat cancer.”